If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Block listing Interim Review

1 Oct 2018 14:57

RNS Number : 5737C
Vernalis PLC
01 October 2018
 

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

 

VERNALIS PLC (the "Company")

 

1 October 2018

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP"); 2012 Value Builder Plan ("VBP"); and

2016 Executive Incentive Plan ("EIP")

Period of return (from / to):

From: 29/Mar/2018

To: 01/Oct/2018

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,149,159 Ordinary 1p Shares, split:

· Under LTIP = 360,485 Ordinary 1p Shares

· Under VBP = 1,788,674 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 166,376 Ordinary 1p Shares, split:

· Under LTIP = 39,405 Ordinary 1p Shares

· Under VBP = 126,971 Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

Total of 30,526 Ordinary 1p Shares:

· Under LTIP = 30,526 Ordinary 1p Shares

· Under VBP = nil Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 1,952,257 Ordinary 1p Shares, split:

· Under LTIP = 290,554 Ordinary 1p Shares

· Under VBP = 1,661,703 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015, plus

1,189,296

1 April 2016, plus

499,612

31 March 2017, plus

1,788,674

2 October 2017, plus

95,654

5 April 2018

 

-- ends --

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 

Canaccord plc (Nominated Adviser and Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel

 

Evercore (Financial Adviser):

+44 (0) 20 7653 6000

Julian Oakley

Alan Beirne

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

 

For further information about Vernalis, please visit www.vernalis.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRMBBJTMBAMBJP
Date   Source Headline
8th Apr 20117:00 amRNSNotice of Results
16th Mar 20117:00 amRNSVernalis Initiates Phase I Trial of V158866
14th Mar 20117:00 amRNSAmericas Licensing Deal for tosedostat
28th Jan 20114:48 pmRNSHolding(s) in Company
21st Dec 20101:11 pmRNSHolding(s) in Company
16th Dec 20107:00 amRNSVernalis and H.Lundbeck A/S enter Collaboration
26th Nov 20104:40 pmRNSSecond Price Monitoring Extn
26th Nov 20104:35 pmRNSPrice Monitoring Extension
18th Nov 20107:00 amRNSInterim Management Statement
18th Nov 20107:00 amRNSVernalis plc: V3381 Programme Update
6th Oct 20107:00 amRNSVernalis and Servier Achieve Research Milestone
29th Jul 20107:00 amRNSInterim results for six months ended 30 June 2010
20th Jul 20104:44 pmRNSNotice of Interim Results
16th Jul 20107:00 amRNSPipeline update
29th Jun 20104:40 pmRNSSecond Price Monitoring Extn
29th Jun 20104:35 pmRNSPrice Monitoring Extension
9th Jun 20103:35 pmRNSHolding(s) in Company
7th Jun 20104:19 pmRNSHolding(s) in Company
4th Jun 20104:40 pmRNSSecond Price Monitoring Extn
4th Jun 20104:35 pmRNSPrice Monitoring Extension
3rd Jun 20103:22 pmRNSHolding(s) in Company
1st Jun 201012:32 pmRNSDirector/PDMR Shareholding
1st Jun 201012:26 pmRNSAGM Statement
19th May 20107:00 amRNSInterim Management Statement
17th May 20104:35 pmRNSPrice Monitoring Extension
4th May 20107:00 amRNSVernalis and Servier extend Oncology Collaboration
27th Apr 20105:16 pmRNSAnnual Information Update
27th Apr 20104:56 pmRNSAGM + Annual Report Notice
16th Apr 20101:17 pmRNSDirector/PDMR Shareholding
16th Apr 20101:16 pmRNSDirector/PDMR Shareholding
12th Apr 20107:00 amRNSAnnouncement of Results year ended 31 Dec 09
1st Apr 201010:30 amRNSNotice of Results
30th Mar 201012:56 pmRNSHolding(s) in Company
24th Mar 20107:00 amRNSIN-STEP Phase IIb study results
15th Mar 20107:00 amRNSVernalis earns milestone
8th Mar 20103:06 pmRNSVernalis Regains European Rights to Frovatriptan
5th Mar 20105:29 pmRNSHolding(s) in Company
5th Mar 20105:28 pmRNSHolding(s) in Company
5th Mar 20105:22 pmRNSHolding(s) in Company
2nd Mar 20105:49 pmRNSVoting Rights and Capital
1st Mar 201012:29 pmRNSResults of General Meeting
1st Mar 20107:00 amRNSPlacing & Open Offer Result
11th Feb 20104:20 pmRNSPublication of Prospectus
11th Feb 20107:00 amRNSPlacing and Open Offer
14th Dec 20097:00 amRNSVernalis announces clinical update
11th Dec 20097:00 amRNSVernalis Earns Milestone Payment
12th Nov 20097:00 amRNSInterim Management Statement
6th Oct 20094:40 pmRNSSecond Price Monitoring Extn
6th Oct 20094:35 pmRNSPrice Monitoring Extension
6th Oct 20097:00 amRNSInitiates Pilot Study of V3381 in Chronic Cough

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.